All News

Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.

Phase 2 CRDF-004 results revealed that adding onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.

Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.

Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.

Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

A phase 0 trial is seeking to assess the feasibility of aiding anticancer cells with cytokines to restore their function.

Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

Data from the DREAMM 7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.

“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Praful Ravi, MB, BChir, MRCP, on the phase 2 LASER trial in RCC.

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Results from the phase 3 GMMG HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.